Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

RECRUITING

I'm interested ...!!

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Conditions:

Psoriasis

Study Start (Actual) 2019-01-16

Primary Completion (Estimated) 2019-09-15

Study Completion (Estimated) 2019-12-15

Enrollment (Estimated) 30

Study Type INTERVENTIONAL

Phase PHASE4

Locations:

📍 East Windsor, New Jersey, United States

Eligibility Criteria

Description

Inclusion Criteria:

* Male or female adult ≥ 18 years of age;
* Diagnosis of chronic plaque-type
* Patient with 2-10% BSA
* Physician Global Assessment of 2 or greater
* Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

Exclusion Criteria:

* ˂2 or \>10% BSA
* PGA \<2
* Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks

Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)

Sexes Eligible for Study: ALL

Accepts Healthy Volunteers: No

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted2019-01-29
First Submitted that Met QC Criteria2019-01-31
First Posted2019-02-04

Study Record Updates

Last Update Submitted that Met QC Criteria2019-01-31
Last Update Posted2019-02-04
Last Verified2019-01